The development of intratumoral hypoxia is a universal hallmark of rapidly growing solid tumors. Adaptation to the hypoxic environment, which is critical for tumor cell survival and growth, is mediated primarily through a hypoxia-inducible factor (HIF)-dependent transcriptional program. HIF activates genes that facilitate crucial adaptive mechanisms including increased glucose uptake and glycolysis and tumor angiogenesis, making it an important therapeutic target. However, the HIF-dependent transcriptional mechanism remains incompletely understood, and targeting HIF is a difficult endeavor. Here, we show that the orphan nuclear receptor estrogen-related receptors (ERRs) physically interact with HIF and stimulate HIF-induced transcription. Importantly, ERRs appear to be essential for HIF's function. Transcriptional activation of hypoxic genes in cells cultured under hypoxia is largely blocked by suppression of ERRs through expression of a dominant negative form of ERR or treatment with a pharmacological ERR inhibitor, diethylstilbestrol. Systematic administration of diethylstilbestrol severely diminished growth and angiogenesis of tumor xenografts in vivo. Because nuclear receptors are outstanding targets for drug discovery, the findings not only may offer mechanistic insights into HIF-mediated transcription but also may open new avenues for targeting the HIF pathway for cancer therapy.
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angiogenesis ͉ energy metabolism ͉ nuclear hormone receptor R apidly growing solid tumors tend to outstrip the supply of oxygen and nutrients provided by blood vessels, resulting in regions of low oxygen levels (hypoxia). Cancer cells undergo adaptation to persist in the hostile hypoxic environment. The adaptive response to hypoxia is controlled primarily by the hypoxia-inducible factor (HIF), a master regulator of hypoxic gene expression and oxygen homeostasis (1) (2) (3) . HIF is a heterodimeric transcription factor comprising an oxygen-regulated ␣-subunit (HIF1␣ or -2␣) and a constitutively expressed and stable ␤-subunit (HIF␤). Under normal oxygen tension, the HIF␣ subunit is subjected to prolyl hydroxylation catalyzed by a set of oxygen-and ferrous ion-dependent prolyl hydroxylases. Hydroxylated HIF␣ is recognized by the tumor-suppressor protein von Hippel-Lindau (VHL), a component of an E3 ubiquitin ligase complex. Subsequently, HIF␣ becomes polyubiquitinated and is targeted for rapid degradation by the proteasomal system. Oxygen deprivation, or administration of iron chelators or cobaltous ion (a classic hypoxia mimetic, which competes with ferrous ion), suppresses hydroxylase activity, allowing HIF␣ to escape the VHL-mediated destruction and to accumulate and dimerize with the constitutively present HIF␤. The binding of the HIF␣-HIF␤ heterodimer along with the transcriptional coactivator p300/CBP to the cognate hypoxia-responsive element (HRE) augments the expression of a plethora of hypoxic genes that carry such elements within their promoters or enhancers (4). The HIF-orchestrated transcriptional program is directly responsible for adaptive mechanisms, such as glycolytic metabolism, angiogenesis, tumor cell survival, invasion, and metastasis.
Cancer cells commonly rely on glycolysis for their energy needs (5, 6) . Glycolysis breaks down glucose to generate pyruvate. Pyruvate is then reduced to lactic acid by lactate dehydrogenase (LDH) or, in the presence of oxygen, is oxidized to acetyl-CoA by the pyruvate dehydrogenase (PDH) enzymatic complex. This step represents an important regulatory point in cellular energy metabolism, because PDH can be switched off by the pyruvate dehydrogenase kinases (PDKs). Acetyl-CoA enters the tricarboxylic acid (TCA) cycle, leading to efficient production of ATP through oxidative phosphorylation (OXPHOS). Under hypoxia, lack of oxygen, the substrate for OXPHOS, restrains cells from the mitochondrial respiratory pathway for ATP generation. To meet tumor cells' high energy demand, HIF strongly stimulates the expression of genes that encode glucose transporters and glycolytic enzymes (including LDH) to accelerate glucose uptake and the anaerobic glycolytic ATP production. In addition, HIF actively attenuates both the TCA cycle and OXPHOS via direct induction of PDK1 (one of the four PDKs) to block conversion of pyruvate to acetyl CoA (7, 8) . This HIF-mediated metabolic switch allows tumor cells to survive and grow under hypoxic environment. Furthermore, HIF activates several angiogenesis-promoting factors (9), including VEGF, which is a dominant growth factor in the tumor angiogenesis cascade. Ultimately, neovascularization may correct the hypoxia and nutrient depletion and consequently aid tumor growth and metastasis.
The HIF-coordinated systemic adaptation contributes substantially to the malignant phenotype. There is mounting clinical evidence correlating tumor hypoxia and HIF overexpression to aggressive tumor behavior, diminished therapeutic response, and increased patient mortality in a broad range of sporadic cancer types (2) . Experimental attenuation of HIF activity by genetic or pharmacological approaches in tumor xenografts and transgenic models leads to markedly reduced tumor size, demonstrating a causal role of HIF in tumor growth and progression (2, 10) . Disruption of individual HIF downstream events such as angiogenesis and glycolysis has shown promising efficacy (6, 11) . Interventions to decrease global HIF activity may even more profoundly prevent tumor cells from adapting to hypoxia, impede angiogenesis, and cause tumor cell death through metabolic derangement.
Given the presence of hypoxia in nearly all solid tumors and the centrality of the HIF pathway in malignancy, pharmacological inhibition of HIF for therapeutics has attracted a great deal of attention. However, transcription factors (except nuclear receptors) are generally not suitable targets for drug discovery, because, unlike enzymes, it is not feasible to identify active site inhibitors. Several cancer drugs that inhibit oncogenic signaling pathways are able to turn down the hypoxic response by indirectly reducing HIF protein synthesis/stability (1, 2) . Recently, the proof of principle for targeting HIF coactivators has been established. Chetomin, a natural compound capable of binding to p300 and causing structural changes, perturbs association of p300 with HIF and induction of hypoxic genes (12) . However, the exact mechanism for HIF-induced transcriptional activation is still uncertain. Genetic studies demonstrate that p300/CBP are responsible for a subset of HIF-stimulated genes and suggest the existence of additional coactivating mechanisms (13) . Moreover, although HIF stabilization and activation under hypoxia are evident in almost all cell types, expression of many HIF target genes exhibits a cell-type-specific pattern. HIF alone cannot account for this cell type specificity. Recent in vivo characterization of a hypoxia-inducible promoter suggested that HRE is required but not sufficient for the hypoxic response. Additional ancillary cis elements are essential in the process, even though the corresponding trans factor(s) has not been identified (14) . Together, these observations further point out the important contributions of potential HIF cofactors to HIF-dependent transcriptional regulation.
Hormone therapy has been used for decades to treat breast cancer. Antiestrogen administration [e.g., the estrogen receptor (ER) antagonist tamoxifen] is applied on the rationale that estrogens stimulate proliferation of breast cancer cells. Paradoxically, the synthetic estrogen diethylstilbestrol (DES) was used clinically to achieve cancer remission (15) . High-dose DES was generally considered the endocrine therapy of choice in women with advanced breast cancer before the introduction of tamoxifen in the 1970s. Tamoxifen became preferable to DES not because of a superior efficacy but rather because of its lower incidence of side effects. The efficacy of the ER antagonist tamoxifen and the ER agonist DES was surprisingly comparable (15, 16) . Survival was even modestly but significantly better for women treated with DES (16) . However, the basis for the beneficial effect of DES is largely elusive.
In the present study, we sought to identify HIF-interacting factors. The estrogen-related receptors (ERRs) (17) , a subgroup of nuclear receptors (NRs), were found to serve as essential cofactors of HIF in mediating the hypoxic response. NR proteins share similar modular structures, including the central DNAbinding domain (DBD) and C-terminal ligand-binding domain (LBD). The DBDs of ERRs are closely related to those of ERs, but the LBDs are more divergent. ERRs are constitutively active orphan receptors. DES can bind and inhibit ERRs (18) . Here, we show that DES blocks the HIF-dependent hypoxic response and tumor xenograft growth.
Results ERRs Interact with HIF.
Response to hypoxia is a fundamental property of living cells. The HIF pathway is highly conserved from fly to human. From a large-scale yeast two-hybrid-based interaction analysis of Drosophila proteins (19) , the fly HIF␣ homolog Sima showed association with an uncharacterized protein CG7404. Based on sequence similarity, CG7404 is the homolog of mammalian ERRs.
ERRs are crucial regulators of energy metabolism (17) . Given the importance of the metabolic switch in adaptation to hypoxia, we decided to further investigate this interaction. We first examined whether mammalian HIF and ERR proteins interacted with each other in vitro by the GST pulldown assay. There are three ERR genes (ERR␣, -␤, and -␥) in human. We fused full-length cDNAs of each ERR to GST and generated fusion proteins in bacteria. We assayed them for binding to in vitro translated full-length HIF1␣, -2␣, and -1␤. All GST ERRs, but not GST itself, exhibited interactions with premixed HIF1␣-HIF1␤ and HIF2␣-HIF1␤ (Fig. 1A) . However, GST ERRs did not bind to single HIF1␤ ( Fig. 1 A) or HIF1␣ (data not shown) when the two HIF subunits were separated, suggesting that ERRs recognized only the functional HIF heterodimers. Given the homology between ERRs and ERs, we examined whether ER␣ might interact with HIF as well. As shown in supporting information (SI) Fig. S1 A, the ER␣-HIF interaction was barely detectable and was much weaker than the ERR-HIF interaction, suggesting that the HIF-ERR interaction is rather specific.
The conformation and activity of NRs can often be modulated by small chemical molecules. The synthetic estrogen DES has been found to act as an antagonist of all three ERRs by disrupting their interactions with coactivators such as p160/SRC (18), whereas the ER antagonist 4-hydroxytamoxifen (4HT) selectively inhibits ERR␥ (17) . We tested whether these compounds might interfere with the ERR-HIF interaction. It was apparent that the ERR␥-HIF association was insensitive to the treatments with DES and 4HT (Fig. 1B) . Similarly, the interactions of HIF with ERR␣ and ERR␤ were not affected by DES either (Fig. 1SB ). These results indicate that HIF may bind to a domain in ERRs, which is different from the one responsible for ERRs' coactivator binding. To map the detailed structural requirements for ERR binding to HIF, we made a series of ERR␤ truncation mutants covering the N terminus, DBD, and LBD. We found that the DBD was involved in HIF binding (Fig.  1C ). This observation is consistent with the chemical treatment result as DES and 4HT bind to the LBD.
We asked whether the ERR-HIF interaction occurred in intact cells. HIF1␣ and ERRs, tagged with the epitopes HA and Flag, respectively, were coexpressed in mammalian cells by transient transfection. When the ERR proteins were immunoprecipitated with the anti-Flag antibodies, HIF1␣ was enriched in the pellets as revealed by Western blot analysis with the anti-HA antibodies (Fig. 1D ). This observation supports that the HIF and ERR proteins form complexes in vivo. We further investigated whether endogenous HIF and ERR proteins might exist in the same complex. The human breast cancer MDA-MB-435 cells were treated with the iron chelator dipyridyl (DP) to stabilize the endogenous HIF␣, and the cellular lysates were subjected to immunoprecipitation with anti-ERR␣ to enrich ERR-associated proteins. HIF1␣ was readily detected in the immunoprecipitates by anti-HIF1␣ Western blot analysis (Fig.  1E) . Together, these results suggest that HIF and ERR proteins physically associate with each other both in vitro and in vivo.
HIF exerts its function by binding to the HREs present in the promoter/enhancer of many hypoxic genes (4) . Given the physical association between HIF and ERR, we questioned whether the ERR proteins would be present at the HIF-bound genes. We chose a few established HIF target genes with well defined HREs, such as VEGF, PDK1, and phosphoglycerate kinase 1 (PGK1), and analyzed potential in vivo promoter binding of HIF and ERR by the ChIP assay. In normoxic cells, chromatin precipitated with the anti-HIF1␣ and -ERR␣ antibodies showed no enrichment of the HIF-dependent genes ( Fig. 2A and Fig. S2 ). However, in DP-treated cells in which HIF␣ was stabilized, occupancy of both HIF1␣ and ERR␣ at the HIF target gene promoters was detected ( Fig. 2 A and Fig. S2 ), suggesting that in response to hypoxia, the ERR proteins are recruited to HIFregulated genes.
ERRs Augment Hypoxic Gene Expression. The presence of ERR at HIF target genes raised the possibility that ERR might directly modulate HIF-mediated gene transcription. We tested this idea by reporter-based assays. A HIF-dependent luciferase reporter containing multiple HREs was readily activated by transfection of the HIF1␣ or -2␣ expression vectors (Fig. 2B) . Although ERR␣ or -␤ alone did not notably affect the reporter, they strongly enhanced the transcriptional activity of HIF␣ (Fig. 2B) . The reporter also responded robustly to increased endogenous HIF activity in cells treated with hypoxic mimetic DP or cobalt (Fig. 2C) . Expression of ERR␣ or -␤ further potentiated reporter activation in these HIF-stabilized cells (Fig. 2C) . Synergistic effects on the hypoxic response by ERR were also observed by using reporters carrying a natural hypoxia-responsive enhancer [e.g., erythropoietin (EPO)] or promoter (e.g., PGK1) ( Fig. 2 D and E) . Therefore, the ERR proteins apparently serve as a positive cofactor of HIF. Consistent with the lack of a strong interaction between ER and HIF, cotransfection of ER␣ (in the presence or absence of its ligand E2) had no effect on HIF's transcriptional activity (data not shown).
Although ERRs are capable of strengthening HIF activity, a critical question is whether they are required for the hypoxic regulation. Genetic studies in mice have shown that mouse mutants deficient for HIF␣, HIF␤, or ERR␤ exhibit strikingly similar phenotypes (20) (21) (22) , suggesting that HIF and ERR may function in the same pathway, and ERR may be an essential component. ERRs are constitutively active orphan receptors. Even in the absence of ligands, ERRs can recruit SRC-1, -2, and -3; PGC1␣ and -␤ (17); and likely other typical NR coactivators as well (e.g., p300/CBP, mediator, and SWI/SNF chromatin remodeling complexes). It is conceivable that ERRs bring these coactivator complexes into close proximity of HIF and boost HIF activity. Because association of ERRs with their coactivators can be regulated by small chemical inhibitors (ref. 17 and Fig. S3 ), we asked whether inhibition of ERRs could serve as a point of intervention in the HIF-mediated hypoxia-responsive pathway. Indeed, activation of the HIF-dependent reporter by DPinduced HIF stabilization was severely impaired by the ERR inhibitor DES (Fig. 2F) , indicating that ERRs may be required for HIF's full activity.
The HIF-mediated hypoxic response is defined by transcriptional activation of many hypoxic genes. We asked whether inhibition of ERR was capable of blocking hypoxia-induced transcription of endogenous genes. As expected, when breast cancer cells (MDA-MB-435 and SKBR3) were cultured under severe hypoxia or treated with DP, known direct target genes of HIF, such as the key angiogenic factor VEGF and glycolytic enzymes, were robustly up-regulated (Fig. 3 A and B) . Interestingly, in the presence of DES, this transcriptional induction was largely abolished (Fig. 3 A and B) . A similar phenomenon was observed in melanoma cells (Fig. 3C) . We examined whether the effect caused by DES was due to its possible influence on HIF␣ protein stability. It seemed that under DES treatment, HIF1␣ was stabilized normally by DP (Fig. 3D ) but remained transcriptionally incompetent. This unique effect of DES distinguished it from several HIF pathway inhibitors, which mainly decrease HIF protein levels (1, 2). We conclude that inhibition of ERRs by DES attenuates the transcriptional activity of HIF.
We explored whether other ERR inhibitors might interfere with the hypoxic response as well. An interesting candidate is resveratrol, which is known to exert a wide range of activities from extending life span to suppressing tumor growth and neovascularization (23) . Resveratrol is capable of dissociating coactivator complexes from all three ERRs, albeit at higher concentrations than DES (18) . Indeed, we found that resveratrol manifested inhibitory activities on the hypoxia-induced gene transcription (Fig. 3E ). This finding also raises the possibility that some of the resveratrol's effects might be attributable to its ability of inhibiting ERRs and the hypoxic response.
To further attest that inhibition of ERRs was accountable for the observed effect of DES on the hypoxic response, we adopted a molecular approach to inactivate ERR. We designed a dominant negative form of ERR (dnERR) to selectively antagonize the activities of all three ERRs. We fused the DBD of ERR␤, which is sufficient for HIF binding (Fig. 1C) , to a transcriptional repression domain of the Drosophila Engrailed protein (24) (Fig.  S4) . The Engrailed domain possesses potent repressive activity when fused to heterologous proteins and has frequently been used to create artificial transcriptional repressors. The ERRengrailed chimeric protein was intended to suppress HIFmediated transcription. We expressed dnERR in the MDA-MB-435 cells by stable transfection. Although the activity of endogenous ERRs was down-regulated (Fig. S4) , the dnERRexpressing cells did not display obvious defects in gross morphology and growth. Under the hypoxic stimulus, however, induction of hypoxic genes was greatly compromised in the dnERR-expressing cells when compared with the control parental cells (Fig. 3F) . Together, this finding supports that blockade of the hypoxic response pathway by pharmacological ERR inhibitors is likely a result of specific inhibition of ERRs.
Systematic Application of DES Inhibits Tumor Xenograft Growth and
Angiogenesis. The HIF-mediated hypoxic response has been shown to be critical for tumor survival and growth in vivo. To extend our studies in cultured cells, we evaluated the effect of ERR inhibition on human tumor cells in a mouse xenograft model. Human breast cancer MDA-MB-435 cells were implanted s.c. into immunodeficient mice and allowed to grow for 2 weeks to establish xenografts before initiation of DES treatment. DES at a dose of 500 g per day per mouse has been shown to cause placental defects in pregnant female mice (18) , which mimic the ERR␤ knockout mutants (20) , strongly suggesting that this dosage is sufficient for inactivation of ERRs in vivo. In our study, each mouse was fed with either vehicle (sesame oil) or 750 g of DES daily, a slightly higher dose than previously reported (18) . There was a dramatic reduction in tumor volumes and growth rate in the DES-administrated mice when compared with the vehicle-treated control animals ( Fig. 4A) . At the end of treatment, tumors were excised and analyzed. Compared with tumors in vehicle-treated mice, DES-treated xenografts were much smaller and weighed approximately three times less (P Ͻ 0.0001) (Fig. 4B) . Because angiogenesis is a key part of the hypoxic response and is required to support tumor growth beyond a certain threshold size, we assessed tumor vascularization by performing immunohistochemical staining by using anti-CD34 antibody. Mouse CD34 is present on endothelial cells and hematopoietic progenitor cells. The antibody recognizes endothelium in vivo, particularly on small vessels and newly formed capillaries and developing vascular structures. CD34 staining revealed abundant vascular capillary formation within the control tumors (Fig. 4C) and a clear reduction of micro vascular density in tumors from the DES-treated animals (P Ͻ 0.001) (Fig. 4D) . Therefore, inhibition of ERR results in retarded tumor growth and diminished tumor angiogenesis in vivo.
Discussion
In the current study, the orphan nuclear receptor ERRs were found to be a positive and essential component of the HIF transcriptional complexes controlling hypoxia-inducible gene expression. The functional collaboration between ERR and HIF is further supported by genetic studies in mice. Physiological hypoxia plays an important role in placental development, and HIF regulates placental morphogenesis, angiogenesis, and cell fate determination. Placentas from mouse embryos lacking the HIF␣ (HIF1␣Ϫ/ϪHIF2␣Ϫ/Ϫ double mutants) or HIF␤ subunits exhibit aberrant placental morphology and decreased vascularization (21, 22) . Hypoxia and HIF promote the in vitro differentiation of trophoblast stem cells into spongiotrophoblasts as opposed to polyploid giant cells (21) . Accordingly, HIF-null placentas display greatly reduced labyrinthine and spongiotrophoblast layers and increased numbers of giant cells (21, 22) . Intriguingly, these phenotypes closely resemble those seen in the ERR␤-deficient placentas (20) . Moreover, treatment of trophoblast stem cells in vitro with DES results in their differentiation toward the giant cell lineage (18) . Hence the genetic and cellular evidence indicates that HIF and ERR may act in a common pathway, supporting our biochemical model that the two factors may form a regulatory complex. The genetic studies also suggest that both HIF and ERR are essential for the pathway. This is in agreement of the blockade of the HIF-dependent response by pharmacological ERR inhibitors or a dominant negative form of ERR.
The unique ERR-HIF connection is consistent with their known functions as established key metabolic regulators. ERRs stimulate genes involved in mitochondrial biogenesis and OX-PHOS (17) . However, this enhanced mitochondrial oxidative capacity is mainly directed at fatty acid metabolism, because ERRs activate medium chain acetyl CoA dehydrogenase (17), a pivotal enzyme involved in fat oxidation, and up-regulate PDK4 to prevent glucose oxidative metabolism (25) (26) (27) . The latter is reminiscent of HIF's activation of PDK1 (7, 8) , which is crucial for the switch from glucose oxidation via the TCA cycle to glycolysis under hypoxia. This shared function on inhibition of glucose respiratory metabolism may represent an intrinsic link between ERR and HIF.
The HIF-dependent hypoxic response has a causal role in tumor growth and progression (1, 2) . Disrupting the ability of tumors to adapt to hypoxia via inactivating key components in the hypoxic response pathway is an attractive antitumor strategy. Inhibition of HIF activity may be effective irrespective of the mode of pathway activation by upstream events. However, HIF itself is difficult to block directly by small-molecule drugs. The interdependence of HIF and ERR suggests that inhibition of ERRs may be a tractable approach to abrogating hypoxiainduced gene expression and malignant progression. The ERR inhibitor DES has exhibited clinically proven antitumor efficacy for advanced breast cancer, although the mechanisms underlying cancer regression are poorly understood (15) . Breast cancer often progresses from an early ER-positive stage to an advanced ER-negative stage. Hypoxia can promote cancer progression by cellular dedifferentiation and down-regulation of ER expression (28, 29) . Highly hypoxic tumors are most likely to be ER-negative (30) . However, increased ERR␣ levels appear to be associated with ER-negative tumor status. In fact, ERR␣ is also a potent prognosis indicator in human breast carcinoma and is significantly associated with an increased risk of recurrence and adverse clinical outcome (31, 32) . However, it remains unclear whether ERR plays a pathogenic role. It is possible that ERR enhances the HIF-mediated hypoxic response and results in a more malignant phenotype. DES treatment may hence block the HIF pathway in advanced cancer cells.
NRs, including ERRs, are generally outstanding therapeutic targets because of their inherent structure to interact with small chemical compounds. The activity of NRs is modulated by ligand binding to their LBDs that results in a conformational change leading to either up-or down-regulation of gene expression. The ligands include many natural and synthetic small lipophilic substances, which can diffuse across the cell membrane. The anticancer efficacy of the existing ERR inhibitor (i.e., DES) holds great promise for developing new ligands with increased potency and selectivity. The crystal structures of ERR LBDs have revealed how inhibitors can promote dissociation of coactivators and potential recruitment of corepressors (17, 33) . This detailed knowledge of the structural mechanism sets the stage for the rational design and rapid identification of new compounds with desired properties for cancer therapy.
Materials and Methods
Plasmids and Antibodies. The HIF-dependent reporter HRE-Luc was generated by inserting two copies of synthetic HRE into the pGL3 luciferase vector (Promega). Epo-Luc and PGK1-Luc were created by cloning the PCR-amplified HIF-dependent enhancer and promoter regions of Epo and PGK1, respectively, into pGL3. Full-length EST clones encoding ERR-␣, -␤, -␥, HIF-1␣, Ϫ2␣, and Ϫ1␤ were used for in vitro translation (Promega TNT kit), production of GST fusions by cloning into the pGEX vector, and mammalian expression by cloning into modified pcDNA3 vectors with Flag or HA epitope tags. ERR deletion mutants were generated by PCR. dnERR was constructed by PCR amplification of ERR␤ DBD and Engrailed repression domain, followed by a three-way ligation into pcDNA3. Anti-Flag, -HA, -ERR␣, and -HIF1␣ antibodies were obtained from Sigma, Covance, Upstate, BD Biosciences, and Novus, respectively.
Cell Lines and Cell Cultures. All human cancer cells were maintained in the following basal media (Invitrogen) supplemented with 10% FBS: breast cancer cell line MDA-MB-435 in DMEM/F12, melanoma WM266 cells in McCoy's 5A, breast cancer SKBR3 in DMEM. Cells were treated with the indicated chemicals (purchased from Sigma): CoCl 2 (300 M), DES (50 M), DP (100 M), and 4HT (10 M). The antibiotic G418 was added in the medium (800 g/ml) for selection of stable dnERR transfectants. A severe hypoxic culture environment was achieved by using a GasPak Pouch System (BD Biosciences), which was capable of reducing the oxygen concentration to less than or equal to 1% (mean percentage: 0.7%).
Northern Blot, GST Binding, Western Blot, Immunoprecipitation (IP), and ChIP. All procedures followed standard molecular biology techniques. For Northern blot assays, total RNA was prepared by using TRIzol (Invitrogen). For GST binding and IP assays, we used the following binding buffer [20 mM Tris, pH 7.5; 150 mM NaCl; 0.5% Nonidet P-40; and protease inhibitor mixture (Roche)]. HIF␣ was found to be not stable under this condition. In later experiments, the proteasome inhibitor MG132 (10 M) was included in the buffer. ChIP assays were performed by using a kit from Upstate, according to the manufacturer's instructions.
Tumor Xenograft Experiment. MDA-MB-435 cells (5 ϫ 10 6 ) were resuspended in a mixture of 100 l of PBS and Matrigel (BD Biosciences; 2:1 ratio) and injected s.c. into the fourth mammary gland fat pad of 6-to 8-week-old female severe combined immunodeficient mice. Two weeks after injection, tumor xenografts became palpable. The mice bearing tumor xenografts were randomly divided into two groups. One group was orally fed daily with 30 l of DES (25 g/l in sesame oil) per mouse, and the control group received 30 l of sesame oil. Tumors were serially measured weekly with a ruler, and the tumor volumes were calculated with the following formula: volume (mm 3 ) ϭ width 2 ϫ length/2. After 3 weeks of treatment, the mice were killed. All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Florida.
Immunohistochemistry. Tumors were dissected at time of necropsy, weighed, and fixed in 4% paraformaldehyde in PBS overnight. Samples were dehydrated in 70% ethanol, paraffin-embedded, and sectioned (5 mm). Deparaffinized sections were stained for CD34 to assess blood vessel density. Briefly, samples were microwaved in sodium citrate (pH 6) for 20 min for antigen retrieval and treated with 3% H 2O2 at room temperature for 20 min to quench endogenous peroxidase activity. Sections were then blocked in 1.5% rabbit serum and incubated with rat anti-mouse CD34 antibody (1:100 dilution, clone MEC14.7, BioLegend), followed by biotinylated rabbit anti-rat IgG (1:200 dilution; Vector Laboratories). Detection was done with avidin-biotin-HRP complex (Vector Laboratories) and di-aminobenzidin as chromogen. Nuclei were counterstained with hematoxylin. Student's t test was performed by a Web tool from the University of Miami.
